FSD Pharma Inc.
HUGE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.88 | 2.10 | 1.04 | 0.72 |
| FCF Yield | -0.46% | -1.45% | -0.92% | -1.57% |
| EV / EBITDA | -136.08 | -87.86 | -76.98 | -46.29 |
| Quality | ||||
| ROIC | -150.16% | -77.13% | -64.37% | -95.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 1.06 | 0.61 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 62.27% | -35.07% | -11.06% | -30.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.73 | 1.17 | 0.65 |
| Interest Coverage | -65,451.89 | -561.83 | -486.19 | -130.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 20,268.05 | 295.80 | 0.00 |
| Cash Conversion Cycle | -463.44 | -231.16 | -271.45 | -183.38 |